Published on Dec 16, 2020 at 9:26 AM
Updated on Dec 16, 2020 at 9:29 AM
  • Analyst Update
Jefferies downgraded MRNA to "hold" from "buy," citing "elevated expectations" as the main reason. However, Jefferies did hit the equity with a price-target hike to $150, while pre-market trading shows Moderna stock is off 4.2%.
Published on Nov 30, 2020 at 10:37 AM
  • Intraday Option Activity
  • Buzz Stocks
Today's options pits are flashing a flurry of activity on both sides of the fence, though calls are still handily outpacing puts. In the first hour of trading, over 78,000 calls and 25,000 puts have already exchanged hands -- four times the intraday average, with volume pacing in the 99th percentile of its annual range.
Published on Nov 18, 2020 at 10:18 AM
Updated on Nov 18, 2020 at 10:18 AM
  • Buzz Stocks
 
Published on Nov 16, 2020 at 10:39 AM
  • Intraday Option Activity
  • Buzz Stocks
In the options pits, there's a whirlwind of activity taking on both sides. In the first hour of trading, over 71,000 calls and 43,000 puts have already exchanged hands -- nine times the intraday average, with volume pacing in the 100th percentile of its annual range.
Published on Nov 12, 2020 at 10:19 AM
  • Intraday Option Activity
  • Buzz Stocks
Moderna announced this morning it had enough data from a late-stage trial to begin a planned interim analysis, though no date was given for when it would report on the vaccine's effectiveness. In response, MRNA is soaring.
Published on Nov 9, 2020 at 9:38 AM
  • Buzz Stocks
 
Published on Oct 22, 2020 at 12:52 PM
Updated on Oct 23, 2020 at 9:22 AM
  • Earnings Preview

Blue-chip pharmaceutical concern Pfizer Inc. (NYSE:PFE) is scheduled to report third-quarter earnings before the market opens on Tuesday, Oct. 27. It's purely coincidental that PFE will report a week before one of the most anticipated elections in U.S. history, especially after U.S. President Donald Trump made comments about an effective COVID-19 vaccine being ready before the election -- comments that Pfizer's CEO refuted concerning its own vaccine. Below, we'll take a look at Pfizer stock's technical setup, as well as its earnings history ahead of an important two week slate.

Although its a notable contender in the race to produce an effective coronavirus vaccine, Pfizer has struggled with its year-to-date breakeven point all 2020. There's support emerging at the $36 area, but overhead $39 --which roughly coincides with that aforementioned year-to-date level -- has stymied PFE's most recent breakout attempts in July and October.

PFE Stock Chart

Optimism is growing in the options pits, where calls are popular. This is per the blue chip's 10-day call/put volume ratio of 10.97 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which is two percentage points from an annual high. In other words, calls are being ordered up at a quicker-than-usual rate in the last two weeks.

PFE has a history of mixed responses following earnings, closing higher in four of the past eight quarters. This includes a 3.9% jump last July, but also a 5% drop last January. Over the past two years, shares have swung an average of 2.9% the day after earnings, regardless of direction. This time around, the options market is pricing in a slightly higher swing of 5.8%.

Published on Oct 20, 2020 at 9:49 AM
  • Buzz Stocks
Moderna said it plans on starting on finishing touches as soon as the potential treatment is approved for emergency use by the Food and Drug Administration (FDA), which could happen as soon as December.
Published on Oct 14, 2020 at 10:43 AM
  • Intraday Option Activity
  • Buzz Stocks
Options traders are responding in kind to today's news. Over 5,000 calls have changed hands already, double the average intraday amount and triple the number of puts traded. 
Published on Oct 13, 2020 at 11:09 AM
Updated on Oct 13, 2020 at 11:10 AM
  • Buzz Stocks
 However, separately, the company was forced to pause a clinical trial of its coronavirus vaccine candidate after a participant in the study came down with an unexplained illness. Johnson & Johnson stock is now down 1.7%, last seen trading at $149.24 this morning.
Published on Oct 7, 2020 at 10:42 AM
  • Analyst Update
  • Buzz Stocks
 
Published on Sep 23, 2020 at 10:59 AM
  • Buzz Stocks
 

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
Special Offers from Schaeffer's Trading Partners


MORE | MARKETstories


This Pot Stock Could Be the Best of 2021
Click to continue to advertiser's site.
All Eyes on Inflation, Jobs Data Next Week
Earnings season is coming to a close, though a few reports will be scattered throughout the week
Options Bulls Eye General Electric Stock After Lofty Bull Note
Morgan Stanley expects sustainable earnings growth for GE in 2023
3 Big Biotech Disruptors For 2021
Click to continue to advertiser's site.